Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2025)

Harmony Biosciences Holdings' Revenue history spans 6 years, with the latest figure at $243.8 million for Q4 2025.

  • For Q4 2025, Revenue rose 21.12% year-over-year to $243.8 million; the TTM value through Dec 2025 reached $868.5 million, up 21.51%, while the annual FY2025 figure was $868.5 million, 21.51% up from the prior year.
  • Revenue for Q4 2025 was $243.8 million at Harmony Biosciences Holdings, up from $239.5 million in the prior quarter.
  • Across five years, Revenue topped out at $243.8 million in Q4 2025 and bottomed at $59.7 million in Q1 2021.
  • The 5-year median for Revenue is $144.4 million (2023), against an average of $145.4 million.
  • The largest annual shift saw Revenue skyrocketed 200.78% in 2021 before it rose 16.01% in 2025.
  • A 5-year view of Revenue shows it stood at $91.2 million in 2021, then surged by 40.67% to $128.3 million in 2022, then surged by 31.26% to $168.4 million in 2023, then increased by 19.51% to $201.3 million in 2024, then grew by 21.12% to $243.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Revenue are $243.8 million (Q4 2025), $239.5 million (Q3 2025), and $200.5 million (Q2 2025).